Fractyl Laboratories is a medical technology company that is developing a minimally invasive, non-surgical treatment for type 2 diabetes. The company's Revita DMR (duodenal mucosal resurfacing) system is designed to improve glycemic control by altering the lining of the duodenum, which is the first part of the small intestine. The Revita DMR system uses a catheter-based approach to deliver radiofrequency energy to the duodenal mucosa, which causes controlled injury and triggers a regenerative response. This process is intended to restore the normal function of the duodenum and improve insulin sensitivity, leading to better glucose control. Fractyl Laboratories was founded in 2011 and is headquartered in Cambridge, Massachusetts.